Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

被引：30

作者：

Sabari, J. K. ^{[1
]}

Shu, C. A. ^{[2
]}

Park, K. ^{[3
]}

Leighl, N. ^{[4
]}

Mitchell, P. ^{[5
]}

Kim, S. ^{[6
]}

Lee, J. ^{[7
]}

Kim, D. ^{[8
]}

Viteri, S. ^{[9
]}

Spira, A. ^{[10
]}

Han, J. ^{[11
]}

Trigo, J. ^{[12
]}

Lee, C. K. ^{[13
]}

Lee, K. H. ^{[14
]}

Girard, N. ^{[15
]}

Yang, T. ^{[16
]}

Goto, K. ^{[17
]}

Sanborn, R. E. ^{[18
]}

Yang, J. C. ^{[19
]}

Xie, J. ^{[20
]}

Roshak, A. ^{[20
]}

Thayu, M. ^{[20
]}

Knoblauch, R. E. ^{[20
]}

Cho, B. C. ^{[21
]}

机构：

[1] NYU, Sch Med, New York, NY USA

[2] Columbia Univ, Med Ctr, New York, NY USA

[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[4] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada

[5] Austin Hosp, Olivia Newton John Canc Wellness & Res Ctr, Heidelberg, Vic, Australia

[6] Asan Med Ctr, Seoul, South Korea

[7] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea

[8] Seoul Natl Univ Hosp, Seoul, South Korea

[9] Inst Oncol Dr Rosell, Ctr Med Teknon, Grp Quironsalud, Barcelona, Spain

[10] Virginia Canc Specialists, Fairfax, VA USA

[11] Natl Canc Ctr, Goyang Si, Gyeonggi Do, South Korea

[12] Hosp Univ Virgen de La Victoria Reg, Malaga, Spain

[13] St George Hosp, Kogarah, NSW, Australia

[14] Chungbuk Natl Univ Hosp, Cheongju, South Korea

[15] Inst Curie, Paris, France

[16] Taichung Vet Gen Hosp, Taichung, Taiwan

[17] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[18] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA

[19] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan

[20] Janssen R&D, Spring House, PA USA

[21] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

amivantamab; Exon20ins; Bispecific antibody;

D O I：

10.1016/j.jtho.2021.01.284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA04.04

引用

页码：S108 / S109

页数：2

共 50 条

[1] Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
Vyse, Simon
Huang, Paul H.
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (01) : 3 - 16
[2] Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib
Russell, Molly C.
Garelli, Alyssa M.
Reeves, David J.
[J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (02) : 198 - 206
[3] Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer
Xie, Yuhao
Lu, Qisi
Wang, Jing-Quan
Bo, Letao
Ashby, Charles R., Jr.
Chen, Zhe-Sheng
[J]. DRUGS OF TODAY, 2022, 58 (08) : 389 - 398
[4] Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis
Girard, N.
Park, K.
Viteri, S.
Schioppa, C. A.
Diels, J.
Oguz, M.
Rodrigues, B. H.
Rahhali, N.
Sermon, J.
Ghilotti, F.
Li, T.
Knoblauch, R. E.
Mahadevia, P.
Cho, B. C.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S38 - S38
[5] EGFR exon 20 insertion mutations in non-small cell lung cancer
Wang, Fenfang
Li, Chenghui
Wu, Qihuan
Lu, Hongyang
[J]. TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2982 - 2991
[6] FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Chon, Katie
Larkins, Erin
Chatterjee, Somak
Mishra-Kalyani, Pallavi S.
Aungst, Stephanie
Wearne, Emily
Subramaniam, Sriram
Li, Yangbing
Liu, Jiang
Sun, Jielin
Charlab, Rosane
Zhao, Hong
Saritas-Yildirim, Banu
Bikkavilli, Rama Kamesh
Ghosh, Soma
Philip, Reena
Beaver, Julia A.
Singh, Harpreet
[J]. CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3262 - 3266
[7] Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
Choi, Dae-Ho
Jung, Hyun Ae
Park, Sehhoon
Sun, Jong -Mu
Ahn, Jin Seok
Ahn, Myung-Ju
Lee, Se-Hoon
[J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (12) : 2448 - 2459
[8] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Simon Vyse
Paul H. Huang
[J]. Signal Transduction and Targeted Therapy, 4
[9] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, Simon
Huang, Paul H.
[J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
[10] Bispecific Approach for Patients with non-small cell Lung Cancer Benefiting from Amivantamab for EGFR-Exon-20-Insertion Mutations
Rudesheim, Sabine M.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 214 - 214

← 1 2 3 4 5 →